NEUP (Neuphoria Therapeutics) Inventory Turnover: 0.00 (As of Mar. 2026)


NEUP Neuphoria Therapeutics Inc NEUP
29 GF Score
Price $3.38
! 1 Warning Sign
View Full Analysis

What is Neuphoria Therapeutics Inventory Turnover?

Neuphoria Therapeutics NEUP -4.52% 29 Inventory Turnover is 0.00 as of Mar. 2026. GuruFocus rates NEUP with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Neuphoria Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil. Neuphoria Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Neuphoria Therapeutics  (NAS:NEUP) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Neuphoria Therapeutics's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=0/0*365 / 4
=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Neuphoria Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Neuphoria Therapeutics Inventory Turnover Related Terms

Neuphoria Therapeutics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Neuphoria Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuphoria Therapeutics Inventory Turnover Chart

Neuphoria Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Neuphoria Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NEUP
29GF Score
Neuphoria Therapeutics Inc NEUP
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuphoria Therapeutics Inventory Turnover Calculation

Neuphoria Therapeutics's Inventory Turnover for the fiscal year that ended in Jun. 2025 is calculated as

Inventory Turnover (A: Jun. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Jun. 2025 ) / ((Total Inventories (A: Jun. 2024 ) + Total Inventories (A: Jun. 2025 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

Neuphoria Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover (Q: Mar. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2026 ) / ((Total Inventories (Q: Dec. 2025 ) + Total Inventories (Q: Mar. 2026 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.00 mean?
Neuphoria Therapeutics (NEUP) has a Inventory Turnover of 0.00 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Neuphoria Therapeutics and its competitors.
Is Neuphoria Therapeutics' Inventory Turnover too high?
Neuphoria Therapeutics' current Inventory Turnover is 0.00. Overall, Neuphoria Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' Inventory Turnover compare to PLRZ and SKYE?
Neuphoria Therapeutics' Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Neuphoria Therapeutics and its competitors. Neuphoria Therapeutics's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current Inventory Turnover of 0.00. The current Inventory Turnover is 0.00. Neuphoria Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Inventory Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuphoria Therapeutics Business Description

Address 100 Summit Drive, Burlington, MA, USA, 01803
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
29GF Score

Get the complete analysis for NEUP

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.38
Price